Leukemia

A long-standing treatment standard for indolent non-Hodgkin lymphoma (NHL) has fallen victim to the chopping block, so to speak, at least in Germany.

Children with acute lymphoblastic leukemia (ALL) had no drop-off in efficacy with an anthracycline-free regimen that also reduced the long-term risk of cardiotoxicity, reported Andre Baruchel, MD, PhD, Chief of Pediatric Hematology, Robert Debré University Hospital, Paris, France.